Biotech firm TuHURA reports $6.3 million in cash equivalents as of March 31, 2026, with R&D expenses totaling $5.2 million for the quarter.
TuHURA Biosciences disclosed a cash and cash equivalents balance of $6.3 million as of March 31, 2026, in its first-quarter results. The company’s outstanding common shares reached approximately 63.6 million.
Research and development expenses for the quarter amounted to $5.2 million, compared with $4.6 million in the prior period. The increase reflects ongoing investment in clinical programs and operational expansion.
No immediate market reaction was detailed in the release.